Stockreport

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

Lixte Biotechnology Holdings, Inc.  (LIXT) 
NASDAQ:AMEX Investor Relations: lixte.com/investor_information_02.php
PDF  -Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13 [Read more]